Overview

SRT in Combination With Pembrolizumab in Patients With Recurrent Prostate Cancer After Radical Prostatectomy

Status:
Not yet recruiting

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy and safety of a pembrolizumab therapy of pembrolizumab in combination with standard salvage radiation therapy (SRT) in patients with biochemical recurrence (BCR) of prostate-specific antigen (PSA) persistence after radical prostatectomy (RP).

Phase:

Phase 2

Details

Lead Sponsor:

Prof. Dr. med. Christian Gratzke

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab